Article about antibiotics and Novartis's decision
Post# of 72436
Quote:
FDA Commissioner Scott Gottlieb published proposals last month to incentivize biopharma investment in antibiotic R&D , including a pull mechanism in which hospitals would pay a fixed licensing fee in return for access to a set number of annual doses of a new antibiotic, rather than reimbursing on a per-use basis.
https://www.fiercebiotech.com/biotech/despite...d=48083647
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)